SciGen and Nas Vax to cooperate on Hep B vaccine
2007-12-13
SciGen, a biopharmaceutical company owned by Polish Bioton, and Nas Vax, a clinical trial company, have signed a joint agreement to develop and commercialise a prophylactic intranasal hepatitis B vaccine.
The product will combine antigens for immunisation against hepatitis B produced by SciGen and a Nas Vax adjuvant technology. Moreover, SciGen will obtain a non-exclusive license to use Nas Vax technology to develop an intramuscular prophylactic hepatitis B vaccine, which will be exercisable during the 12 months after the execution of the agreement.
The world market for hepatitis B vaccines is estimated at about $1.3bn (€886m).
Established in 1988, SciGen develops and markets biopharmaceutical products for human health care, focusing mainly on gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.
Nas Vax, founded in 2004, is mainly engaged in clinical trials (Phase I/IIa). It is also developing an improved vaccine against the influenza virus and performing pre-clinical trials on vaccines against anthrax, avian flu and hepatitis B.
PMR Online Access
Browse and search in our archive »
Subscribe to PMR RSS NEWS channels » 
